Company: NIVFW
Filing Date: 2025-10-31
Form Type: 424B3
Source: 0001213900-25-104469
Chunk: 142

Company: NewGenIvf Group Ltd
Filing Date: 2025-10-31
Form: 424B3
Chunk 142
---
 2024 (2025 for calendar-year
entities). This update aims to reduce ambiguity in tax reporting and align disclosures with investor needs.

In March 2024, the FASB issued
ASU No. 2024-01, Compensation-Stock Compensation (Topic 718): Scope Application of Profits Interest and Similar Awards, which provides
illustrative guidance to help entities determine whether profits interest and similar awards should be accounted for as share-based payment
arrangements within the scope of ASC 718. ASU 2024-01 is effective for annual periods beginning after December 15, 2024, and interim
periods within those annual periods. The Group is currently evaluating the impact of the adoption of ASU 2024-01 on its consolidated
financial statements and related disclosures.”

A major shift in digital
asset accounting, ASU 2023-08 requires companies to measure certain crypto assets (e.g., Bitcoin, Ethereum) at fair value rather than
applying the previous impairment-only model. This means entities must recognize quarterly fair value adjustments in their financial statements,
increasing volatility in reported earnings but improving transparency. The standard applies to fiscal years beginning after December
15, 2024, and impacts both corporate treasuries and investment firms holding cryptocurrencies. This change aligns GAAP closer to fair
value accounting seen in other investment holdings, addressing criticisms of the old impairment approach.

In March 2025, the FASB issued
ASU 2025-02, Liabilities (Topic 405): Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 122. (“ASU 2025-02”)
which amends the Accounting Standards Codification to remove the text of SEC Staff Accounting Bulletin (“SAB”) 121 “Accounting
for Obligations to Safeguard Crypto-Assets an Entity Holds for its Platform Users” as it has been rescinded by the issuance of
SAB 122. ASU 2025-02 is effective immediately and on a fully retrospective basis to annual periods beginning after December 15, 2024.
It is not expected to have an impact on the Company’s consolidated financial statements.

<div align='center'>BUSINESS</div>

Overview

We are an assisted reproductive
services (“ARS”) provider in Asia-Pacific. Since the opening of our first clinic in Thailand in 2014, we have established
ourself as a long-standing ARS provider in this region. Our strategic presence in Thailand